Skip to search formSkip to main contentSkip to account menu

CISCA protocol

Known as: CISCA, CISCA Regimen, Cisplatin-Cytoxan-Adriamycin Regimen 
A regimen consisting of cisplatin, cyclophosphamide and doxorubicin used for the treatment of advanced bladder cancer.
National Institutes of Health

Related topics

Related topics

5 relations

Broader (2)

Antineoplastic Combined Chemotherapy ProtocolsCyclophosphamide
Carcinoma of bladderCisplatinDoxorubicin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A Class-Information-Based Sparse Component Analysis Method to Identify Differentially Expressed Genes on RNA-Seq Data
With the development of deep sequencing technologies, many RNA-Seq data have been generated. Researchers have proposed many… 
Highly Cited
2008
Highly Cited
2008
Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and…
PURPOSE Two chemotherapy regimens for intermediate- and poor-risk metastatic nonseminomatous germ cell tumors were compared for… 
Highly Cited
2006
Highly Cited
2006
CISCA (cisplatin vs. carboplatin) meta-analysis: An individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell…
7011 Background: The issue of the equivalence between carboplatin and cisplatin in the treatment of advanced NSCLC is still… 
2002
2002
Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours
Only about half of patients with a poor-prognosis non-seminomatous germ-cell tumours can achieve a cure. The aim of this phase II… 
2002
2002
A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III…
BACKGROUND This prospective randomized clinical trial was designed to compare the efficacy of a low-dose regimen of cisplatin… 
Highly Cited
1988
Highly Cited
1988
Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update.
Seventy-one patients received adjuvant Cytoxan (cyclophosphamide; Bristol-Myers Co, Evansville, IN), Adriamycin (doxorubicin… 
Highly Cited
1985
Highly Cited
1985
Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C.
1985
1985
Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CISCA) in the management of select patients with invasive urothelial tumors.
Twenty-eight patients with unresectable urothelial tumors who had no evidence of distant visceral metastasis were managed with iv… 
1984
1984
Current status of adjuvant chemotherapy after radical cystectomy for deeply invasive bladder cancer.
Highly Cited
1977
Highly Cited
1977
Combination chemotherapy (CISCA) for advanced urinary tract carcinoma. A preliminary report.
Twelve patients with metastatic transitional cell carcinoma from the urinary bladder were treated with a combination chemotherapy… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)